Somewhat Favorable News Coverage Somewhat Unlikely to Affect Agile Therapeutics (AGRX) Stock Price
Media stories about Agile Therapeutics (NASDAQ:AGRX) have trended somewhat positive on Friday, Accern Sentiment Analysis reports. The research group identifies positive and negative media coverage by monitoring more than twenty million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Agile Therapeutics earned a media sentiment score of 0.20 on Accern’s scale. Accern also gave media coverage about the specialty pharmaceutical company an impact score of 47.2596296517153 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the next several days.
These are some of the news headlines that may have impacted Accern Sentiment’s scoring:
- Technical Alerts – Agile Therapeutics, Inc. (AGRX) stock worth at $5.04 – Wall Street Morning (wallstreetmorning.com)
- Agile Therapeutics, Inc. (AGRX) Stock Rating Reaffirmed by Cantor Fitzgerald (americanbankingnews.com)
- Agile Therapeutics, Inc. (AGRX) Given Consensus Rating of “Buy” by Analysts (americanbankingnews.com)
- Corium Q4 Sales Top Expectations Ahead Of Slew Of Near-Term Catalysts – Benzinga (benzinga.com)
Several research analysts have recently weighed in on AGRX shares. Royal Bank Of Canada increased their price target on Agile Therapeutics from $8.00 to $10.00 and gave the stock an “outperform” rating in a research note on Thursday, September 14th. HC Wainwright set a $10.00 price target on Agile Therapeutics and gave the stock a “buy” rating in a research note on Thursday, October 12th. Cantor Fitzgerald reiterated a “buy” rating and set a $8.00 price target on shares of Agile Therapeutics in a research note on Monday, November 6th. Janney Montgomery Scott reiterated a “buy” rating and set a $13.00 price target on shares of Agile Therapeutics in a research note on Thursday, September 7th. Finally, ValuEngine downgraded Agile Therapeutics from a “sell” rating to a “strong sell” rating in a research note on Friday, September 1st. One research analyst has rated the stock with a sell rating and six have issued a buy rating to the company’s stock. The stock has an average rating of “Buy” and an average target price of $10.20.
Agile Therapeutics (NASDAQ:AGRX) traded up $0.12 during mid-day trading on Friday, hitting $5.16. The stock had a trading volume of 351,000 shares, compared to its average volume of 368,006. The company has a quick ratio of 4.10, a current ratio of 4.10 and a debt-to-equity ratio of 0.14. Agile Therapeutics has a 12 month low of $1.82 and a 12 month high of $7.09.
Agile Therapeutics (NASDAQ:AGRX) last posted its quarterly earnings results on Monday, November 6th. The specialty pharmaceutical company reported ($0.22) earnings per share for the quarter, topping the consensus estimate of ($0.25) by $0.03. equities analysts forecast that Agile Therapeutics will post -0.99 EPS for the current year.
WARNING: This report was published by Watch List News and is owned by of Watch List News. If you are reading this report on another domain, it was illegally copied and reposted in violation of U.S. and international copyright and trademark law. The legal version of this report can be read at https://www.watchlistnews.com/somewhat-favorable-news-coverage-somewhat-unlikely-to-affect-agile-therapeutics-agrx-stock-price/1724278.html.
Agile Therapeutics Company Profile
Agile Therapeutics, Inc is a women’s health specialty pharmaceutical company. The Company is focused in the development and commercialization of prescription contraceptive products. The Company has developed a transdermal patch technology, called Skinfusion. The Company’s lead product candidate is Twirla, also known as AG200-15, is a combined hormonal contraceptive (CHC) patch.
Receive News & Ratings for Agile Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agile Therapeutics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.